Jun 27, 2023 / 08:00AM GMT
Erik Manting - Mendus AB - CEO
Welcome everybody to this morning's webcast. Of course, end of last year, we had an exciting update of the ADVANCE II monotherapy trial. And more recently, we announced how we want to move forward with the program that comprises, on the one hand, a clinical path forward; and on the other hand, an important manufacturing alliance, which we announced with NorthX. Today, we will guide you through an overview of what that means and how we will all move forward from here.
Next slide is the disclaimer, which is also on our website. And the next slide is today's program and speakers. I will give a brief introduction about members, which you would be familiar. And then hand it over to Ted Fjällman, who is Board member at NorthX and CEO of Flerie, to say a few words about NorthX. And also, Flerie's investment model.
And then I will hand it over to my colleagues. First, Leopold Bertea, our Chief Technology Officer, to say more about vividencel manufacturing and the importance of that for the program. And then over to Jeroen Rovers, our Chief Medical Officer to guide
Mendus AB (publ) Update on Vididencel Program Transcript
Jun 27, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers